Italia markets close in 2 hours 7 minutes

FTSE MIB
34.517,15
-307,86(-0,88%)
Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
78,65
-1,15(-1,44%)
Bitcoin EUR
65.412,94
+3.639,84(+5,89%)

NVCR Dec 2025 7.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,4500

0,0000

(0,00%)

In data: 02:28PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in